Healthcare >> CEO Interviews >> March 3, 2000
THOMAS G. LYNCH is a Graduate in Economics of The Queen's University in
Belfast and a Fellow of the Institute of Chartered Accountants in
Ireland. Subsequent to university, Mr. Lynch joined the accounting firm
KPMG Peat Marwick in 1980 and worked in that firm's audit and accounting
practice between 1980 and 1993. Mr. Lynch held a variety of positions in
that firm between 1980 and 1990 when he was elected a partner. Mr. Lynch
specialized in the provision of business advisory and accounting
services to publicly held corporations and to a number of the firm's
banking and financial services clients. In 1993, Mr. Lynch was appointed
Executive Vice President and Chief Financial Officer of Elan
Corporation, plc, a leading biopharmaceutical company, and serves as a
member of its Board of Directors. He is responsible for finance,
treasury, government affairs, strategic planning and corporate and
investor relations. Mr. Lynch is a Director of Nanogen, Inc. and is
Chairman of the Audit and Compensation Committee of the Board, (a
developer of genetic testing systems and genomics research), Pembroke
Capital Limited (an aviation finance company) and ICON plc (a clinical
research organization) and is Chairman of its Audit Committee. Mr. Lynch
has substantial experience in securities markets (in the US and
elsewhere); merger and acquisition activity (Elan has made seven
acquistions since 1993) and corporate finance (Mr. Lynch has had
responsibility for financing activity in excess of $2 billion since he
joined Elan in 1993. Profile
Mr. Lynch: Elan is a biotechnology and drug delivery company that last
year recorded revenues in excess of $1 billion, with net income of $350
million.
